Ivan Krečak
← Back to Šibenik University of Applied Sciences
Šibenik University of Applied Sciences
Ivan Krečak works in Myeloproliferative Neoplasms: Diagnosis and Treatment, Platelet Disorders and Treatments, Chronic Lymphocytic Leukemia Research, Hematological disorders and diagnostics, Venous Thromboembolism Diagnosis and Management. Recorded institutional associations include University of Rijeka, Šibenik University of Applied Sciences, Opća bolnica Šibenik.
Inclusion identifies researchers whose recorded research contributions may inform their university’s understanding of its research community. It does not rank individual research quality or establish current employment.
Selected research works
Up to 100 highly cited works; DOI links open the original research. Counts reflect the collected record, not real-time citation totals.
Thrombocytosis in COVID-19 patients without myeloproliferative neoplasms is associated with better prognosis but higher rate of venous thromboembolism
2021 · 35 citationsReduced renal function strongly affects survival and thrombosis in patients with myelofibrosis
2020 · 34 citationsIdentifying Patients with Polycythemia Vera at Risk of Thrombosis after Hydroxyurea Initiation: The Polycythemia Vera—Advanced Integrated Models (PV-AIM) Project
2023 · 31 citationsChronic kidney disease could be a risk factor for thrombosis in essential thrombocythemia and polycythemia vera
2020 · 29 citationsAdvances in Risk Stratification and Treatment of Polycythemia Vera and Essential Thrombocythemia
2022 · 24 citationsHigh red blood cell distribution width might predict thrombosis in essential thrombocythemia and polycythemia vera
2019 · 23 citationsNeutrophil‐to‐lymphocyte and platelet‐to‐lymphocyte ratios as prognostic biomarkers in polycythemia vera
2021 · 21 citationsThe impact of statins on the intensity of phlebotomies in polycythemia vera
2020 · 20 citationsRenal disease associated with chronic myeloproliferative neoplasms
2022 · 19 citationsThrombotic risk in secondary polycythemia resembles low-risk polycythemia vera and increases in specific subsets of patients
2021 · 17 citationsPatients with post polycythemia vera myelofibrosis might experience increased thrombotic risk in comparison to primary and post essential thrombocythemia myelofibrosis
2022 · 17 citationsHigher serum uric acid is associated with higher risks of thrombosis and death in patients with primary myelofibrosis
2021 · 16 citationsHigh platelet-to-lymphocyte ratio may differentiate polycythemia vera from secondary polycythemia
2022 · 15 citationsPolypharmacy, Potentially Inappropriate Medications, and Drug-to-Drug Interactions in Patients with Chronic Myeloproliferative Neoplasms
2023 · 15 citationsThe triple A model (age, absolute neutrophil count, absolute lymphocyte count‐ AAA ) predicts survival and thrombosis in polycythemia vera
2024 · 15 citationsEstimating plasma volume using the Strauss‐derived formula may improve prognostication in polycythemia vera
2021 · 13 citationsNo Impact of the Increased Number of Cardiovascular Risk Factors on Thrombosis and Survival in Polycythemia Vera
2021 · 12 citationsHigher estimated plasma volume status is associated with increased thrombotic risk and impaired survival in patients with primary myelofibrosis
2023 · 12 citationsHyperuricemia might promote thrombosis in essential thrombocythemia and polycythemia vera
2020 · 11 citationsLow-density lipoprotein (LDL) and the risk of thrombotic events in essential thrombocythemia and polycythemia vera
2021 · 11 citationsBeneficial effect of ACE inhibitors on kidney function in polycythemia vera
2021 · 11 citationsC reactive protein to albumin ratio as prognostic marker in primary and secondary myelofibrosis
2020 · 10 citationsOptimization of cardiovascular risk factor management in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms, current knowledge, and perspectives
2023 · 10 citationsEvaluation of Absolute Neutrophil, Lymphocyte and Platelet Count and Their Ratios as Predictors of Thrombotic Risk in Patients with Prefibrotic and Overt Myelofibrosis
2024 · 10 citationsCirculating YKL-40 in Philadelphia-negative myeloproliferative neoplasms
2019 · 9 citations
